Skip to main content
Clinical benefit of granulocyte-colony stimulating factor (GCSF) use during chemoimmunotherapy treatment for metastatic pancreatic adenocarcinoma (mPDAC). Lyman, J. P., Cabanski, C. R., Maddock, S., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Rahma, O. E., Fisher, G. A., Gabriel, P., Doucette, A., Zheng-Lin, B., Maloy, M. A., Dugan, U., Fairchild, J. P., Spasic, M., O'Donnell-Tormey, J., Vonderheide, R. H., O'Hara, M. H., O'Reilly, E. LIPPINCOTT WILLIAMS & WILKINS. 2023: 757

View details for Web of Science ID 001093994600772